Pharmacologic Agents for Diabetes & Obesity Infographic-Pharmacologic Agents for Diabetes & Obesity Infographic

Pharmacologic Agents for Diabetes & Obesity Infographic

Pdf Summary

This document provides an overview of pharmacologic treatment options for diabetes and obesity, based on the American Diabetes Association's (ADA) 2024 Standards of Care. It highlights the importance of incretins and weight management in type 2 diabetes. Effective obesity management can significantly delay the progression from prediabetes to type 2 diabetes, improve glycemic control, and reduce the need for glucose-lowering medications. This management is also associated with meaningful weight loss and reduced obesity-related health risks.<br /><br />Key treatment options for individuals with type 2 diabetes and obesity include intensive behavioral counseling, obesity pharmacotherapy, and bariatric surgery. The document emphasizes considering an individual's weight when choosing glucose-lowering medications and minimizing medications associated with weight gain. For individuals with a BMI over 27 kg/m², obesity pharmacotherapy can be an effective adjunct treatment, alongside nutrition, physical activity, and behavioral counseling.<br /><br />The efficacy of glucose-lowering medications in promoting weight loss is categorized as very high, high, intermediate, or neutral. Some highly effective medications include semaglutide, tirzepatide, and liraglutide, among others. <br /><br />When initiating obesity pharmacotherapy, a 5% weight loss after three months is generally considered effective. If this response is insufficient or safety and tolerability issues arise, it may be necessary to reevaluate treatment, considering discontinuation, substitution, or additional therapeutic approaches.<br /><br />The document stresses individualized treatment and careful consideration of potential benefits and risks associated with each pharmacologic option. For more information, individuals are encouraged to contact the ADA or visit their website.

Keywords

diabetes

obesity

ADA Standards of Care

incretins

type 2 diabetes

obesity pharmacotherapy

bariatric surgery

glucose-lowering medications

semaglutide

liraglutide